Campbell & CO Investment Adviser LLC Acquires New Position in Globus Medical, Inc. $GMED

Campbell & CO Investment Adviser LLC acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 9,420 shares of the medical device company’s stock, valued at approximately $539,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its position in Globus Medical by 189.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 476,531 shares of the medical device company’s stock worth $27,953,000 after acquiring an additional 312,149 shares during the period. Paradice Investment Management LLC grew its holdings in shares of Globus Medical by 20.9% during the 3rd quarter. Paradice Investment Management LLC now owns 663,038 shares of the medical device company’s stock worth $37,972,000 after purchasing an additional 114,433 shares during the period. Boston Trust Walden Corp acquired a new stake in shares of Globus Medical during the 3rd quarter worth about $67,891,000. American Century Companies Inc. raised its holdings in Globus Medical by 123.5% in the 2nd quarter. American Century Companies Inc. now owns 298,221 shares of the medical device company’s stock valued at $17,601,000 after buying an additional 164,813 shares during the period. Finally, Janney Montgomery Scott LLC raised its holdings in Globus Medical by 4.6% in the 2nd quarter. Janney Montgomery Scott LLC now owns 18,908 shares of the medical device company’s stock valued at $1,116,000 after buying an additional 840 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on GMED. Morgan Stanley lifted their price target on shares of Globus Medical from $70.00 to $100.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Canaccord Genuity Group increased their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Wells Fargo & Company lifted their target price on shares of Globus Medical from $66.00 to $79.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Barclays upped their price target on Globus Medical from $106.00 to $114.00 and gave the stock an “overweight” rating in a research note on Monday, November 10th. Finally, Citigroup reaffirmed a “market perform” rating on shares of Globus Medical in a research note on Thursday, January 8th. Eight equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.78.

Insider Buying and Selling

In other news, CFO Kyle Kline sold 18,542 shares of Globus Medical stock in a transaction on Monday, December 1st. The shares were sold at an average price of $90.00, for a total transaction of $1,668,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen T. Zarrilli sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $84.29, for a total transaction of $2,107,250.00. The disclosure for this sale is available in the SEC filing. Insiders have sold 91,636 shares of company stock valued at $7,984,583 over the last ninety days. 18.51% of the stock is currently owned by corporate insiders.

Globus Medical Trading Up 1.3%

NYSE:GMED opened at $94.16 on Thursday. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The firm has a market cap of $12.60 billion, a PE ratio of 30.37, a price-to-earnings-growth ratio of 1.38 and a beta of 1.06. The stock has a fifty day moving average price of $88.92 and a 200 day moving average price of $69.84.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, November 6th. The medical device company reported $1.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.39. The company had revenue of $769.05 million for the quarter, compared to analyst estimates of $734.58 million. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.Globus Medical’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.83 EPS. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. Equities analysts forecast that Globus Medical, Inc. will post 3.44 EPS for the current year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.